Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.

Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD, Field AS, Boland J, Fabry Z.

Mult Scler. 2011 Jun;17(6):743-54. doi: 10.1177/1352458511398054. Epub 2011 Mar 3.

2.

Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial.

Rosche B, Wernecke KD, Ohlraun S, Dörr JM, Paul F.

Trials. 2013 Apr 25;14:112. doi: 10.1186/1745-6215-14-112.

3.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

PMID:
25698173
4.

Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.

Fleming J, Hernandez G, Hartman L, Maksimovic J, Nace S, Lawler B, Risa T, Cook T, Agni R, Reichelderfer M, Luzzio C, Rolak L, Field A, Fabry Z.

Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377. [Epub ahead of print]

PMID:
29064315
5.

Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients.

Benzel F, Erdur H, Kohler S, Frentsch M, Thiel A, Harms L, Wandinger KP, Rosche B.

J Helminthol. 2012 Sep;86(3):339-47. doi: 10.1017/S0022149X11000460. Epub 2011 Aug 15.

PMID:
21838960
6.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
7.

Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer.

Williams AR, Dige A, Rasmussen TK, Hvas CL, Dahlerup JF, Iversen L, Stensvold CR, Agnholt J, Nejsum P.

Immunol Lett. 2017 Aug;188:32-37. doi: 10.1016/j.imlet.2017.06.002. Epub 2017 Jun 8.

PMID:
28602842
8.

Oral simvastatin treatment in relapsing-remitting multiple sclerosis.

Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I.

Lancet. 2004 May 15;363(9421):1607-8.

PMID:
15145635
9.

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dörr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F.

PLoS One. 2008 Apr 9;3(4):e1928. doi: 10.1371/journal.pone.0001928.

10.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A.

PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.

11.

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.

Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB.

Aliment Pharmacol Ther. 2013 Aug;38(3):255-63. doi: 10.1111/apt.12366. Epub 2013 Jun 3.

12.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
13.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
14.

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.

Mult Scler Relat Disord. 2014 Nov;3(6):696-704. doi: 10.1016/j.msard.2014.08.002. Epub 2014 Aug 29.

15.

Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis.

Cavaletti G, Perseghin P, Dassi M, Cavarretta R, Frigo M, Caputo D, Stanzani L, Tagliabue E, Zoia C, Grimaldi M, Isella V, Rota S, Ferrarese C, Frattola L.

Neurol Sci. 2006 Apr;27(1):24-32.

PMID:
16688596
16.

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group.

Neurology. 2005 Mar 22;64(6):987-91.

PMID:
15781813
17.

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DA.

Arch Neurol. 2008 Aug;65(8):1044-51. doi: 10.1001/archneurol.65.8.noc80042. Epub 2008 Jun 9.

18.

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH.

Neurology. 2010 Jun 8;74(23):1860-7. doi: 10.1212/WNL.0b013e3181e24373.

19.

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.

Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.

BMC Neurol. 2006 May 23;6:19.

20.

Fingolimod for relapsing-remitting multiple sclerosis.

La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G.

Cochrane Database Syst Rev. 2016 Apr 19;4:CD009371. doi: 10.1002/14651858.CD009371.pub2. Review.

PMID:
27091121

Supplemental Content

Support Center